1 Antihyperuricemic Agents Market Overview
1.1 Product Overview and Scope of Antihyperuricemic Agents
1.2 Antihyperuricemic Agents Segment by Type
1.2.1 Global Antihyperuricemic Agents Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Inhibit Uric Acid Production Agents
1.2.3 Promote Uric Acid Excretion Agents
1.2.4 Others
1.3 Antihyperuricemic Agents Segment by Distribution Channel
1.3.1 Global Antihyperuricemic Agents Sales Comparison by Distribution Channel: (2022-2028)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Antihyperuricemic Agents Market Size Estimates and Forecasts
1.4.1 Global Antihyperuricemic Agents Revenue 2017-2028
1.4.2 Global Antihyperuricemic Agents Sales 2017-2028
1.4.3 Antihyperuricemic Agents Market Size by Region: 2017 Versus 2021 Versus 2028
2 Antihyperuricemic Agents Market Competition by Manufacturers
2.1 Global Antihyperuricemic Agents Sales Market Share by Manufacturers (2017-2022)
2.2 Global Antihyperuricemic Agents Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Antihyperuricemic Agents Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Antihyperuricemic Agents Manufacturing Sites, Area Served, Product Type
2.5 Antihyperuricemic Agents Market Competitive Situation and Trends
2.5.1 Antihyperuricemic Agents Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Antihyperuricemic Agents Players Market Share by Revenue
2.5.3 Global Antihyperuricemic Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antihyperuricemic Agents Retrospective Market Scenario by Region
3.1 Global Antihyperuricemic Agents Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Antihyperuricemic Agents Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Antihyperuricemic Agents Market Facts & Figures by Country
3.3.1 North America Antihyperuricemic Agents Sales by Country
3.3.2 North America Antihyperuricemic Agents Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Antihyperuricemic Agents Market Facts & Figures by Country
3.4.1 Europe Antihyperuricemic Agents Sales by Country
3.4.2 Europe Antihyperuricemic Agents Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Antihyperuricemic Agents Market Facts & Figures by Region
3.5.1 Asia Pacific Antihyperuricemic Agents Sales by Region
3.5.2 Asia Pacific Antihyperuricemic Agents Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Antihyperuricemic Agents Market Facts & Figures by Country
3.6.1 Latin America Antihyperuricemic Agents Sales by Country
3.6.2 Latin America Antihyperuricemic Agents Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Antihyperuricemic Agents Market Facts & Figures by Country
3.7.1 Middle East and Africa Antihyperuricemic Agents Sales by Country
3.7.2 Middle East and Africa Antihyperuricemic Agents Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Antihyperuricemic Agents Historic Market Analysis by Type
4.1 Global Antihyperuricemic Agents Sales Market Share by Type (2017-2022)
4.2 Global Antihyperuricemic Agents Revenue Market Share by Type (2017-2022)
4.3 Global Antihyperuricemic Agents Price by Type (2017-2022)
5 Global Antihyperuricemic Agents Historic Market Analysis by Distribution Channel
5.1 Global Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)
5.2 Global Antihyperuricemic Agents Revenue Market Share by Distribution Channel (2017-2022)
5.3 Global Antihyperuricemic Agents Price by Distribution Channel (2017-2022)
6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Corporation Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
6.2 Hikma
6.2.1 Hikma Corporation Information
6.2.2 Hikma Description and Business Overview
6.2.3 Hikma Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Hikma Antihyperuricemic Agents Product Portfolio
6.2.5 Hikma Recent Developments/Updates
6.3 Wockhardt
6.3.1 Wockhardt Corporation Information
6.3.2 Wockhardt Description and Business Overview
6.3.3 Wockhardt Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Wockhardt Antihyperuricemic Agents Product Portfolio
6.3.5 Wockhardt Recent Developments/Updates
6.4 West Ward Pharmaceuticals
6.4.1 West Ward Pharmaceuticals Corporation Information
6.4.2 West Ward Pharmaceuticals Description and Business Overview
6.4.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.4.4 West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolio
6.4.5 West Ward Pharmaceuticals Recent Developments/Updates
6.5 Rhea Pharmaceutical
6.5.1 Rhea Pharmaceutical Corporation Information
6.5.2 Rhea Pharmaceutical Description and Business Overview
6.5.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolio
6.5.5 Rhea Pharmaceutical Recent Developments/Updates
6.6 Medinova
6.6.1 Medinova Corporation Information
6.6.2 Medinova Description and Business Overview
6.6.3 Medinova Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Medinova Antihyperuricemic Agents Product Portfolio
6.6.5 Medinova Recent Developments/Updates
6.7 Odan Laboratories
6.6.1 Odan Laboratories Corporation Information
6.6.2 Odan Laboratories Description and Business Overview
6.6.3 Odan Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Odan Laboratories Antihyperuricemic Agents Product Portfolio
6.7.5 Odan Laboratories Recent Developments/Updates
6.8 TEIJIN
6.8.1 TEIJIN Corporation Information
6.8.2 TEIJIN Description and Business Overview
6.8.3 TEIJIN Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.8.4 TEIJIN Antihyperuricemic Agents Product Portfolio
6.8.5 TEIJIN Recent Developments/Updates
6.9 Casper Pharma
6.9.1 Casper Pharma Corporation Information
6.9.2 Casper Pharma Description and Business Overview
6.9.3 Casper Pharma Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Casper Pharma Antihyperuricemic Agents Product Portfolio
6.9.5 Casper Pharma Recent Developments/Updates
6.10 Dr. Reddys Laboratories
6.10.1 Dr. Reddys Laboratories Corporation Information
6.10.2 Dr. Reddys Laboratories Description and Business Overview
6.10.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolio
6.10.5 Dr. Reddys Laboratories Recent Developments/Updates
6.11 Teva
6.11.1 Teva Corporation Information
6.11.2 Teva Antihyperuricemic Agents Description and Business Overview
6.11.3 Teva Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Teva Antihyperuricemic Agents Product Portfolio
6.11.5 Teva Recent Developments/Updates
6.12 Zydus Pharmaceuticals
6.12.1 Zydus Pharmaceuticals Corporation Information
6.12.2 Zydus Pharmaceuticals Antihyperuricemic Agents Description and Business Overview
6.12.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolio
6.12.5 Zydus Pharmaceuticals Recent Developments/Updates
6.13 Mylan
6.13.1 Mylan Corporation Information
6.13.2 Mylan Antihyperuricemic Agents Description and Business Overview
6.13.3 Mylan Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Mylan Antihyperuricemic Agents Product Portfolio
6.13.5 Mylan Recent Developments/Updates
6.14 Sun Pharmaceutical
6.14.1 Sun Pharmaceutical Corporation Information
6.14.2 Sun Pharmaceutical Antihyperuricemic Agents Description and Business Overview
6.14.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Sun Pharmaceutical Antihyperuricemic Agents Product Portfolio
6.14.5 Sun Pharmaceutical Recent Developments/Updates
6.15 APOTEX
6.15.1 APOTEX Corporation Information
6.15.2 APOTEX Antihyperuricemic Agents Description and Business Overview
6.15.3 APOTEX Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.15.4 APOTEX Antihyperuricemic Agents Product Portfolio
6.15.5 APOTEX Recent Developments/Updates
6.16 NorthStar Healthcare
6.16.1 NorthStar Healthcare Corporation Information
6.16.2 NorthStar Healthcare Antihyperuricemic Agents Description and Business Overview
6.16.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.16.4 NorthStar Healthcare Antihyperuricemic Agents Product Portfolio
6.16.5 NorthStar Healthcare Recent Developments/Updates
6.17 Ipca Laboratories
6.17.1 Ipca Laboratories Corporation Information
6.17.2 Ipca Laboratories Antihyperuricemic Agents Description and Business Overview
6.17.3 Ipca Laboratories Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Ipca Laboratories Antihyperuricemic Agents Product Portfolio
6.17.5 Ipca Laboratories Recent Developments/Updates
6.18 Accord Healthcare
6.18.1 Accord Healthcare Corporation Information
6.18.2 Accord Healthcare Antihyperuricemic Agents Description and Business Overview
6.18.3 Accord Healthcare Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Accord Healthcare Antihyperuricemic Agents Product Portfolio
6.18.5 Accord Healthcare Recent Developments/Updates
6.19 Gentec Pharmaceutical Group
6.19.1 Gentec Pharmaceutical Group Corporation Information
6.19.2 Gentec Pharmaceutical Group Antihyperuricemic Agents Description and Business Overview
6.19.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolio
6.19.5 Gentec Pharmaceutical Group Recent Developments/Updates
6.20 Indoco Remedies
6.20.1 Indoco Remedies Corporation Information
6.20.2 Indoco Remedies Antihyperuricemic Agents Description and Business Overview
6.20.3 Indoco Remedies Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Indoco Remedies Antihyperuricemic Agents Product Portfolio
6.20.5 Indoco Remedies Recent Developments/Updates
6.21 Lupin
6.21.1 Lupin Corporation Information
6.21.2 Lupin Antihyperuricemic Agents Description and Business Overview
6.21.3 Lupin Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Lupin Antihyperuricemic Agents Product Portfolio
6.21.5 Lupin Recent Developments/Updates
6.22 Waterstone Pharmaceuticals
6.22.1 Waterstone Pharmaceuticals Corporation Information
6.22.2 Waterstone Pharmaceuticals Antihyperuricemic Agents Description and Business Overview
6.22.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.22.4 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolio
6.22.5 Waterstone Pharmaceuticals Recent Developments/Updates
6.23 ALP Pharm
6.23.1 ALP Pharm Corporation Information
6.23.2 ALP Pharm Antihyperuricemic Agents Description and Business Overview
6.23.3 ALP Pharm Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.23.4 ALP Pharm Antihyperuricemic Agents Product Portfolio
6.23.5 ALP Pharm Recent Developments/Updates
6.24 Jiangsu Hengrui Medicine
6.24.1 Jiangsu Hengrui Medicine Corporation Information
6.24.2 Jiangsu Hengrui Medicine Antihyperuricemic Agents Description and Business Overview
6.24.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.24.4 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolio
6.24.5 Jiangsu Hengrui Medicine Recent Developments/Updates
6.25 Jiangsu Wanbang Biopharmaceuticals
6.25.1 Jiangsu Wanbang Biopharmaceuticals Corporation Information
6.25.2 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Description and Business Overview
6.25.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.25.4 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolio
6.25.5 Jiangsu Wanbang Biopharmaceuticals Recent Developments/Updates
6.26 Hangzhou Zhuyangxin Pharmaceutical
6.26.1 Hangzhou Zhuyangxin Pharmaceutical Corporation Information
6.26.2 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Description and Business Overview
6.26.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.26.4 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolio
6.26.5 Hangzhou Zhuyangxin Pharmaceutical Recent Developments/Updates
6.27 YiChang HEC ChangJiang Pharmaceutical
6.27.1 YiChang HEC ChangJiang Pharmaceutical Corporation Information
6.27.2 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Description and Business Overview
6.27.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.27.4 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolio
6.27.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
6.28 KPC Pharmaceuticals
6.28.1 KPC Pharmaceuticals Corporation Information
6.28.2 KPC Pharmaceuticals Antihyperuricemic Agents Description and Business Overview
6.28.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.28.4 KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolio
6.28.5 KPC Pharmaceuticals Recent Developments/Updates
6.29 Tonghua Limin
6.29.1 Tonghua Limin Corporation Information
6.29.2 Tonghua Limin Antihyperuricemic Agents Description and Business Overview
6.29.3 Tonghua Limin Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.29.4 Tonghua Limin Antihyperuricemic Agents Product Portfolio
6.29.5 Tonghua Limin Recent Developments/Updates
6.30 Beijing Jialin Pharmaceutical
6.30.1 Beijing Jialin Pharmaceutical Corporation Information
6.30.2 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Description and Business Overview
6.30.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Revenue and Gross Margin (2017-2022)
6.30.4 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolio
6.30.5 Beijing Jialin Pharmaceutical Recent Developments/Updates
7 Antihyperuricemic Agents Manufacturing Cost Analysis
7.1 Antihyperuricemic Agents Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Antihyperuricemic Agents
7.4 Antihyperuricemic Agents Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Antihyperuricemic Agents Distributors List
8.3 Antihyperuricemic Agents Customers
9 Antihyperuricemic Agents Market Dynamics
9.1 Antihyperuricemic Agents Industry Trends
9.2 Antihyperuricemic Agents Market Drivers
9.3 Antihyperuricemic Agents Market Challenges
9.4 Antihyperuricemic Agents Market Restraints
10 Global Market Forecast
10.1 Antihyperuricemic Agents Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Antihyperuricemic Agents by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Antihyperuricemic Agents by Type (2023-2028)
10.2 Antihyperuricemic Agents Market Estimates and Projections by Distribution Channel
10.2.1 Global Forecasted Sales of Antihyperuricemic Agents by Distribution Channel (2023-2028)
10.2.2 Global Forecasted Revenue of Antihyperuricemic Agents by Distribution Channel (2023-2028)
10.3 Antihyperuricemic Agents Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Antihyperuricemic Agents by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Antihyperuricemic Agents by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Antihyperuricemic Agents Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Antihyperuricemic Agents Sales Growth Rate Comparison by Distribution Channel (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Antihyperuricemic Agents Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Antihyperuricemic Agents Market Competitive Situation by Manufacturers in 2021
Table 5. Global Antihyperuricemic Agents Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Antihyperuricemic Agents Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Antihyperuricemic Agents Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Antihyperuricemic Agents Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Antihyperuricemic Agents Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Antihyperuricemic Agents Manufacturing Sites and Area Served
Table 11. Manufacturers Antihyperuricemic Agents Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Antihyperuricemic Agents by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antihyperuricemic Agents as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Antihyperuricemic Agents Sales by Region (2017-2022) & (K Units)
Table 16. Global Antihyperuricemic Agents Sales Market Share by Region (2017-2022)
Table 17. Global Antihyperuricemic Agents Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Antihyperuricemic Agents Revenue Market Share by Region (2017-2022)
Table 19. North America Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 20. North America Antihyperuricemic Agents Sales Market Share by Country (2017-2022)
Table 21. North America Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Antihyperuricemic Agents Revenue Market Share by Country (2017-2022)
Table 23. Europe Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 24. Europe Antihyperuricemic Agents Sales Market Share by Country (2017-2022)
Table 25. Europe Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Antihyperuricemic Agents Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Antihyperuricemic Agents Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Antihyperuricemic Agents Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Antihyperuricemic Agents Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Antihyperuricemic Agents Revenue Market Share by Region (2017-2022)
Table 31. Latin America Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Antihyperuricemic Agents Sales Market Share by Country (2017-2022)
Table 33. Latin America Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Antihyperuricemic Agents Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Antihyperuricemic Agents Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Antihyperuricemic Agents Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Antihyperuricemic Agents Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Antihyperuricemic Agents Revenue Market Share by Country (2017-2022)
Table 39. Global Antihyperuricemic Agents Sales by Type (2017-2022) & (K Units)
Table 40. Global Antihyperuricemic Agents Sales Market Share by Type (2017-2022)
Table 41. Global Antihyperuricemic Agents Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Antihyperuricemic Agents Revenue Share by Type (2017-2022)
Table 43. Global Antihyperuricemic Agents Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Antihyperuricemic Agents Sales (K Units) by Distribution Channel (2017-2022)
Table 45. Global Antihyperuricemic Agents Sales Market Share by Distribution Channel (2017-2022)
Table 46. Global Antihyperuricemic Agents Revenue by Distribution Channel (2017-2022) & (US$ Million)
Table 47. Global Antihyperuricemic Agents Revenue Share by Distribution Channel (2017-2022)
Table 48. Global Antihyperuricemic Agents Price by Distribution Channel (2017-2022) & (US$/Unit)
Table 49. Takeda Pharmaceuticals Corporation Information
Table 50. Takeda Pharmaceuticals Description and Business Overview
Table 51. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Takeda Pharmaceuticals Antihyperuricemic Agents Product
Table 53. Takeda Pharmaceuticals Recent Developments/Updates
Table 54. Hikma Corporation Information
Table 55. Hikma Description and Business Overview
Table 56. Hikma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Hikma Antihyperuricemic Agents Product
Table 58. Hikma Recent Developments/Updates
Table 59. Wockhardt Corporation Information
Table 60. Wockhardt Description and Business Overview
Table 61. Wockhardt Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Wockhardt Antihyperuricemic Agents Product
Table 63. Wockhardt Recent Developments/Updates
Table 64. West Ward Pharmaceuticals Corporation Information
Table 65. West Ward Pharmaceuticals Description and Business Overview
Table 66. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. West Ward Pharmaceuticals Antihyperuricemic Agents Product
Table 68. West Ward Pharmaceuticals Recent Developments/Updates
Table 69. Rhea Pharmaceutical Corporation Information
Table 70. Rhea Pharmaceutical Description and Business Overview
Table 71. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Rhea Pharmaceutical Antihyperuricemic Agents Product
Table 73. Rhea Pharmaceutical Recent Developments/Updates
Table 74. Medinova Corporation Information
Table 75. Medinova Description and Business Overview
Table 76. Medinova Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Medinova Antihyperuricemic Agents Product
Table 78. Medinova Recent Developments/Updates
Table 79. Odan Laboratories Corporation Information
Table 80. Odan Laboratories Description and Business Overview
Table 81. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Odan Laboratories Antihyperuricemic Agents Product
Table 83. Odan Laboratories Recent Developments/Updates
Table 84. TEIJIN Corporation Information
Table 85. TEIJIN Description and Business Overview
Table 86. TEIJIN Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. TEIJIN Antihyperuricemic Agents Product
Table 88. TEIJIN Recent Developments/Updates
Table 89. Casper Pharma Corporation Information
Table 90. Casper Pharma Description and Business Overview
Table 91. Casper Pharma Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Casper Pharma Antihyperuricemic Agents Product
Table 93. Casper Pharma Recent Developments/Updates
Table 94. Dr. Reddys Laboratories Corporation Information
Table 95. Dr. Reddys Laboratories Description and Business Overview
Table 96. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Dr. Reddys Laboratories Antihyperuricemic Agents Product
Table 98. Dr. Reddys Laboratories Recent Developments/Updates
Table 99. Teva Corporation Information
Table 100. Teva Description and Business Overview
Table 101. Teva Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Teva Antihyperuricemic Agents Product
Table 103. Teva Recent Developments/Updates
Table 104. Zydus Pharmaceuticals Corporation Information
Table 105. Zydus Pharmaceuticals Description and Business Overview
Table 106. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. Zydus Pharmaceuticals Antihyperuricemic Agents Product
Table 108. Zydus Pharmaceuticals Recent Developments/Updates
Table 109. Mylan Corporation Information
Table 110. Mylan Description and Business Overview
Table 111. Mylan Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Mylan Antihyperuricemic Agents Product
Table 113. Mylan Recent Developments/Updates
Table 114. Sun Pharmaceutical Corporation Information
Table 115. Sun Pharmaceutical Description and Business Overview
Table 116. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Sun Pharmaceutical Antihyperuricemic Agents Product
Table 118. Sun Pharmaceutical Recent Developments/Updates
Table 119. APOTEX Corporation Information
Table 120. APOTEX Description and Business Overview
Table 121. APOTEX Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 122. APOTEX Antihyperuricemic Agents Product
Table 123. APOTEX Recent Developments/Updates
Table 124. NorthStar Healthcare Corporation Information
Table 125. NorthStar Healthcare Description and Business Overview
Table 126. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 127. NorthStar Healthcare Antihyperuricemic Agents Product
Table 128. NorthStar Healthcare Recent Developments/Updates
Table 129. Ipca Laboratories Corporation Information
Table 130. Ipca Laboratories Description and Business Overview
Table 131. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 132. Ipca Laboratories Antihyperuricemic Agents Product
Table 133. Ipca Laboratories Recent Developments/Updates
Table 134. Accord Healthcare Corporation Information
Table 135. Accord Healthcare Description and Business Overview
Table 136. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 137. Accord Healthcare Antihyperuricemic Agents Product
Table 138. Accord Healthcare Recent Developments/Updates
Table 139. Gentec Pharmaceutical Group Corporation Information
Table 140. Gentec Pharmaceutical Group Description and Business Overview
Table 141. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 142. Gentec Pharmaceutical Group Antihyperuricemic Agents Product
Table 143. Gentec Pharmaceutical Group Recent Developments/Updates
Table 144. Indoco Remedies Corporation Information
Table 145. Indoco Remedies Description and Business Overview
Table 146. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 147. Indoco Remedies Antihyperuricemic Agents Product
Table 148. Indoco Remedies Recent Developments/Updates
Table 149. Lupin Corporation Information
Table 150. Lupin Description and Business Overview
Table 151. Lupin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 152. Lupin Antihyperuricemic Agents Product
Table 153. Lupin Recent Developments/Updates
Table 154. Waterstone Pharmaceuticals Corporation Information
Table 155. Waterstone Pharmaceuticals Description and Business Overview
Table 156. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 157. Waterstone Pharmaceuticals Antihyperuricemic Agents Product
Table 158. Waterstone Pharmaceuticals Recent Developments/Updates
Table 159. ALP Pharm Corporation Information
Table 160. ALP Pharm Description and Business Overview
Table 161. ALP Pharm Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 162. ALP Pharm Antihyperuricemic Agents Product
Table 163. ALP Pharm Recent Developments/Updates
Table 164. Jiangsu Hengrui Medicine Corporation Information
Table 165. Jiangsu Hengrui Medicine Description and Business Overview
Table 166. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 167. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product
Table 168. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 169. Jiangsu Wanbang Biopharmaceuticals Corporation Information
Table 170. Jiangsu Wanbang Biopharmaceuticals Description and Business Overview
Table 171. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 172. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product
Table 173. Jiangsu Wanbang Biopharmaceuticals Recent Developments/Updates
Table 174. Hangzhou Zhuyangxin Pharmaceutical Corporation Information
Table 175. Hangzhou Zhuyangxin Pharmaceutical Description and Business Overview
Table 176. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 177. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product
Table 178. Hangzhou Zhuyangxin Pharmaceutical Recent Developments/Updates
Table 179. YiChang HEC ChangJiang Pharmaceutical Corporation Information
Table 180. YiChang HEC ChangJiang Pharmaceutical Description and Business Overview
Table 181. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 182. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product
Table 183. YiChang HEC ChangJiang Pharmaceutical Recent Developments/Updates
Table 184. KPC Pharmaceuticals Corporation Information
Table 185. KPC Pharmaceuticals Description and Business Overview
Table 186. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 187. KPC Pharmaceuticals Antihyperuricemic Agents Product
Table 188. KPC Pharmaceuticals Recent Developments/Updates
Table 189. Tonghua Limin Corporation Information
Table 190. Tonghua Limin Description and Business Overview
Table 191. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 192. Tonghua Limin Antihyperuricemic Agents Product
Table 193. Tonghua Limin Recent Developments/Updates
Table 194. Beijing Jialin Pharmaceutical Corporation Information
Table 195. Beijing Jialin Pharmaceutical Description and Business Overview
Table 196. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 197. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product
Table 198. Beijing Jialin Pharmaceutical Recent Developments/Updates
Table 199. Production Base and Market Concentration Rate of Raw Material
Table 200. Key Suppliers of Raw Materials
Table 201. Antihyperuricemic Agents Distributors List
Table 202. Antihyperuricemic Agents Customers List
Table 203. Antihyperuricemic Agents Market Trends
Table 204. Antihyperuricemic Agents Market Drivers
Table 205. Antihyperuricemic Agents Market Challenges
Table 206. Antihyperuricemic Agents Market Restraints
Table 207. Global Antihyperuricemic Agents Sales Forecast by Type (2023-2028) & (K Units)
Table 208. Global Antihyperuricemic Agents Sales Market Share Forecast by Type (2023-2028)
Table 209. Global Antihyperuricemic Agents Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 210. Global Antihyperuricemic Agents Revenue Market Share Forecast by Type (2023-2028)
Table 211. Global Antihyperuricemic Agents Sales Forecast by Distribution Channel (2023-2028) & (K Units)
Table 212. Global Antihyperuricemic Agents Sales Market Share Forecast by Distribution Channel (2023-2028)
Table 213. Global Antihyperuricemic Agents Revenue Forecast by Distribution Channel (2023-2028) & (US$ Million)
Table 214. Global Antihyperuricemic Agents Revenue Market Share Forecast by Distribution Channel (2023-2028)
Table 215. Global Antihyperuricemic Agents Sales Forecast by Region (2023-2028) & (K Units)
Table 216. Global Antihyperuricemic Agents Sales Market Share Forecast by Region (2023-2028)
Table 217. Global Antihyperuricemic Agents Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 218. Global Antihyperuricemic Agents Revenue Market Share Forecast by Region (2023-2028)
Table 219. Research Programs/Design for This Report
Table 220. Key Data Information from Secondary Sources
Table 221. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antihyperuricemic Agents
Figure 2. Global Antihyperuricemic Agents Market Share by Type in 2021 & 2028
Figure 3. Inhibit Uric Acid Production Agents Product Picture
Figure 4. Promote Uric Acid Excretion Agents Product Picture
Figure 5. Others Product Picture
Figure 6. Global Antihyperuricemic Agents Market Share by Distribution Channel in 2021 & 2028
Figure 7. Hospital Pharmacies
Figure 8. Retail Pharmacies
Figure 9. Online Pharmacies
Figure 10. Global Antihyperuricemic Agents Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Antihyperuricemic Agents Market Size (2017-2028) & (US$ Million)
Figure 12. Global Antihyperuricemic Agents Sales (2017-2028) & (K Units)
Figure 13. Antihyperuricemic Agents Sales Share by Manufacturers in 2021
Figure 14. Global Antihyperuricemic Agents Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Antihyperuricemic Agents Players: Market Share by Revenue in 2021
Figure 16. Antihyperuricemic Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Antihyperuricemic Agents Sales Market Share by Region (2017-2022)
Figure 18. Global Antihyperuricemic Agents Sales Market Share by Region in 2021
Figure 19. Global Antihyperuricemic Agents Revenue Market Share by Region (2017-2022)
Figure 20. Global Antihyperuricemic Agents Revenue Market Share by Region in 2021
Figure 21. United States Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Taiwan Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Colombia Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Turkey Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Saudi Arabia Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. UAE Antihyperuricemic Agents Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Sales Market Share of Antihyperuricemic Agents by Type (2017-2022)
Figure 45. Manufacturing Cost Structure of Antihyperuricemic Agents
Figure 46. Manufacturing Process Analysis of Antihyperuricemic Agents
Figure 47. Antihyperuricemic Agents Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
